Journal of Neuroimmune Pharmacology

, Volume 5, Issue 1, pp 1–3 | Cite as

Advances in the “Omics” for Diagnosis, Pathogenesis, and Therapeutic Development

  • Howard S. FoxEmail author
Guest Commentary

The advent of the data-intense “omic” techniques has brought wonderful new techniques and insights into biomedical science but has raised questions regarding the use and role of these technologies. The proper balance between exploratory and directed studies in science is a difficult and old subject, harkening back the formation of the scientific method in which the observation step is critical, but in which we are also instructed to observe in order to test a specific hypothesis. However, the “omic” revolution has now allowed the determination of a large amount of data with often near-similar ease as measuring one or several analytes that by themselves could address the question at hand. So the order of events, hypothesis, experimental model, data gathering and analysis, followed by successive cycles, has for some been upended in a sense in that large amounts of data can be obtained and themselves used to form the hypotheses and model construction for experimental testing.



Cocaine Omic Human Brain Postmortem Scripps Research Institute Small Regulatory RNAs 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material


(MPG 103 Mb)


  1. Achur RN, Freeman WM, Vrana KE (2010) Circulating cytokines as biomarkers of alcohol abuse and alcoholism. J Neuroimmune Pharmacol. doi: 10.1007/s11481-009-9185-z
  2. Borjabad A, Brooks AI, Volsky DJ (2010) Gene expression profiles of HIV-1-infected glia and brain: toward better understanding of the role of astrocytes in HIV-1-associated neurocognitive disorders. J Neuroimmune Pharmacol. doi: 10.1007/s11481-009-9167-1
  3. Gelman BB, Nguyen TP (2010) Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes. J Neuroimmune Pharmacol. doi: 10.1007/s11481-009-9168-0
  4. Go EP (2010) Database resources in metabolomics: an overview. J Neuroimmune Pharmacol. doi: 10.1007/s11481-009-9157-3
  5. Hemby SE (2010) Cocainomics: insights into in gene and protein expression following cocaine. J Neuroimmune Pharmacol 5. doi: 10.1007/s11481-009-9189-8
  6. Nordstrom A, Lewensohn R (2010) Metabolomics: moving to the clinic. J Neuroimmune Pharmacol. doi: 10.1007/s11481-009-9156-4
  7. Sugiura Y, Setou M (2010) Imaging mass spectrometry for visualization of drug and endogenous metabolite distribution: toward in situ pharmacometabolomes. J Neuroimmune Pharmacol. doi: 10.1007/s11481-009-9162-6
  8. Yelamanchili SV, Fox HS (2010) Defining larger roles for “Tiny” RNA molecules: role of miRNAs in neurodegeneration research. J Neuroimmune Pharmacol. doi: 10.1007/s11481-009-9172-4

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Pharmacology and Experimental NeuroscienceUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations